Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-08T05:37:08.887Z Has data issue: false hasContentIssue false

Managing the Integration of Technologies: Development of the Immunoassay

Published online by Cambridge University Press:  10 March 2009

Tamara J. Erickson
Affiliation:
Arthur D. Little, Inc.

Abstract

Many factors, including cultural, economic, technical, and regulatory influences, affect how different technologies come together for today's medical diagnostic products. An analysis of the development of automated immunoassay systems reveals that companies used a variety of approaches to access needed technologies, that mature technologies play an important role in the development of new products, and that implementation seemed more important in these companies than strategy.

Type
Special Section: Industry and the Generation of Technology
Copyright
Copyright © Cambridge University Press 1993

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bernson, S. A., & Yalow, R. S.Recent studies on insulin-binding antibodies. Annals of the New York Academy of Sciences, 1959, 82, 338–44.CrossRefGoogle Scholar
2.Koehler, G., & Milstein, C.Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 495–97.CrossRefGoogle Scholar
3.Roberts, E. B. Managing technological innovation in the medical device industry. Research Technology Management, 1989, 07-08, 3441.CrossRefGoogle Scholar
4.Rubenstein, K. E., Schneider, R. S., & Ullman, E. F. “Homogeneous” enzyme immunoassay. A new immunochemical technique. Biochemical and Biophysical Research Communications, 1972, 846–51.CrossRefGoogle Scholar